Loading
A phase 2 trial of Cisplatin, Gemcitabine and Bevacizumab in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] is a phase 2 interventional study registered as NCT07111546 by Nanjing Leads Biolabs Co.,Ltd, with 140 participants planned, started 2025-10-20 and due to reach its primary completion in 2027-12-26. Interventions recorded: LBL-024 for Injection, Cisplatin Injection, Gemcitabine Hydrochloride for Injection and Bevacizumab Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Nanjing Leads Biolabs, Cisplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BTC, Gemcitabine and the tag pipeline.
Shares Gemcitabine, Cisplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares Gemcitabine, Cisplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/